Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis
- 22 June 2020
- journal article
- research article
- Published by S. Karger AG in International Archives of Allergy and Immunology
- Vol. 181 (8), 613-617
- https://doi.org/10.1159/000508559
Abstract
Introduction: Mepolizumab is a monoclonal antibody against IL-5 for the treatment of severe eosinophilic asthma. The aim of the current study was to present a predesigned interim analysis of the data of patients who have completed 1 year of therapy with mepolizumab. Methods: This study is a prospective multicenter, noninterventional 2-year observational study and aims to describe the clinical benefit and safety profile of mepolizumab in patients with severe eosinophilic asthma. Results: Compared to the year preceding the initiation of treatment, the annual rate of exacerbations decreased significantly, from 4.3 ± 2.3 to 1.3 ± 1.8; p < 0.0001. Forty-two patients received maintenance dose of oral corticosteroids (OCS) at baseline. From these patients at the end of 1 year of therapy with mepolizumab, 17 patients (40%) had achieved OCS discontinuation. A reduction in the median dose of OCS was also achieved. After 1 year of treatment with mepolizumab, the asthma control test score significantly increased from 16.3 ± 3.7 to 21.2 ± 3.8 (p < 0.0001). This marked clinical improvement was paralleled by a significant reduction of blood eosinophil count. All patients showed a considerable improvement of airflow limitation. In respect to adverse events of treatment with mepolizumab, 19 patients (27%) were recorded to have at least one such occurrence during their 1-year treatment. Conclusions: We have shown that in patients with severe eosinophilic asthma, 1 year of treatment with mepolizumab was safe, resulted in significant reduction of the annual exacerbation rate, reduction (or even discontinuation) of the needed dose of OCS, and improvements of asthma control and lung function.Keywords
This publication has 10 references indexed in Scilit:
- The Cellular Functions of Eosinophils: Collegium Internationale Allergologicum (CIA) Update 2020International Archives of Allergy and Immunology, 2019
- Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthmaJournal of Asthma, 2019
- One year of mepolizumab. Efficacy and safety in real-life in ItalyPulmonary Pharmacology & Therapeutics, 2019
- Biologicals targeting type 2 immunity: Lessons learned from asthma, chronic urticaria and atopic dermatitisEuropean Journal of Immunology, 2019
- Real-life evaluation of the clinical, functional, and hematological effects of mepolizumab in patients with severe eosinophilic asthma: Results of a single-centre observational studyPulmonary Pharmacology & Therapeutics, 2018
- Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trialThe Lancet Respiratory Medicine, 2017
- Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studiesThe Lancet Respiratory Medicine, 2016
- Oral Glucocorticoid-Sparing Effect of Mepolizumab in Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Mepolizumab Treatment in Patients with Severe Eosinophilic AsthmaThe New England Journal of Medicine, 2014
- Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trialThe Lancet, 2012